A Phase 3 interventional study of Romiplostim in Thrombocytopenia and Idiopathic Thrombocytopenic Purpura, sponsored by Amgen. Completed. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2013-12-18.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 3rd largest by enrollment, is the only one that started in 2004, is one of 13 in phase 3, and was the 4th registered.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
Browse Purpura, Thrombocytopenic, Idiopathic studies →5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–100
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14+
Wuhan Union Hospital, China · Sites in China
Ages 18–75
Nahda University · Sites in Egypt
Ages 18–65
By country, each count listing its studies:
romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.
This study: 1 Year and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 13 · Phase 4 3
First in 2002; this study’s year is marked. 1 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 313 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Median enrollment 62 across the 29 interventional studies. Of the 20 that completed or were terminated, 12 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 29 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen: 1 open now, 1 under way, 1 of them phase 3. Of 17 finished, 13 (76%) have results posted.
Among the 18 studies in Purpura, Thrombocytopenic, Idiopathic by Amgen, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2004, is one of 10 in phase 3, and was the 4th registered.
Amgen’s Purpura, Thrombocytopenic, Idiopathic studies by the year they started, since 2002.
2 of the studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07206823The First Affiliated Hospital of Soochow UniversityEfficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia | 2027-02-28 |
| NCT07612319The First Affiliated Hospital of Soochow UniversityRomiplostim for Oral TPO-RA Resistant ITP | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Amgen’s 18 in Purpura, Thrombocytopenic, Idiopathic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety of romiplostim as a long-term treatment in thrombocytopenic subjects with ITP, to evaluate the long-term platelet response to romiplostim, and to evaluate changes in patient reported outcomes due to the use of romiplostim. Participants must have previously completed a romiplostim ITP study.
504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.
This study's enrollment of 313 is above the median of 58 across 377 interventional studies indexed under Purpura, Thrombocytopenic, Idiopathic.
Browse Purpura, Thrombocytopenic, Idiopathic studies →Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Compared within Purpura, Thrombocytopenic, Idiopathic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thrombocytopenia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Romiplostim weekly subcutaneous dosing based on screening weight and platelet count. Starting dose of 1 µg/kg up to a maximum dose of 10 µg/kg.
Biological: Romiplostim
Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Also known as: AMG 531, Nplate
Number of Participants With Adverse Events
Participants with one or more occurrences of one or more adverse events up to 8 weeks after the end of treatment. Participants with more than one event were only counted once.
Time frame: Duration of treatment plus 8 weeks (up to 285 weeks)
Number of Participants With a Platelet Response
Platelet response was defined as having a platelet count of ≥ 50 x 10\^9/L at any time on study, excluding platelet counts within 8 weeks after receiving any rescue medications.
Time frame: Duration of treatment (up to 277 weeks)
Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies
The number of participants with a reduction or discontinuation of concurrent immune (idiopathic) thrombocytopenic purpura (ITP) therapies (corticosteroids, danazol, azathioprine) during the study.
Time frame: Duration of treatment (up to 277 weeks)
Change From Baseline in ITP Patient Assessment Questionnaire
The ITP Patient Assessment Questionnaire (ITP-PAQ) assesses ITP-specific health-related quality of life (HRQOL). This questionnaire assesses ITP specific health-related quality of life (HRQOL). The questionnaire consists of 44 items and has six domains: These domains assess the impact of ITP on Physical Health, Mental Health, Work, Social Activity, Women's Health and Overall QOL. The impact of ITP on Physical Health consists of four sub-scales, which evaluate ITP related Symptoms, Fatigue, Bother and Activity. The impact of ITP on Mental Health consists of two sub-scales, which evaluate Psychological distress and Fear in a population with ITP. Items are scored from 0-100 with higher scores indicating better HRQOL.
Time frame: Baseline to Week 48
Change From Baseline in Short Form 36 (SF-36)
The SF-36 is a widely used generic health-related quality of life measure. It has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Items are scored from 0 to 100 with higher scores indicating better health status.
Time frame: Baseline to Week 48
Change From Baseline in Euroqol-5D (EQ-5D) Index Score
The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The instrument is applicable to a wide range of health conditions and treatments and results in a single index score and a visual analog scale (VAS) score. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state is defined by combining one level from each of the five dimensions. EQ-5D index values range from -0.59 to 1.00. Higher EQ-5D Index scores represent better health status.
Time frame: Baseline to Week 48
Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS)
The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The EQ-5D VAS records the respondent's self-rated health status on a vertical graduated (0-100) visual analogue scale. Higher EQ-5D VAS scores represent better health status.
Time frame: Baseline to Week 48
Patient Global Assessment
The Patient Global Assessment is two questions which assess the overall health-related quality of life (HRQOL) and symptoms of the patient. Each item is answered on a 15-point Likert scale ranging from 'A very great deal worse' (1) to 'A very great deal better' (15). A higher score indicates that quality of life or symptoms have improved.
Time frame: Week 1 and Week 48
Participants were enrolled from 2 August 2004 through 15 April 2009
| Milestone | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| Started | 292 | 21 |
| Received study medication | 291 | 20 |
| Completed | 200 | 17 |
| Not completed | 92 | 4 |
| Withdrew: Protocol deviation | 1 | 0 |
| Withdrew: Noncompliance | 3 | 1 |
| Withdrew: Adverse event | 11 | 0 |
| Withdrew: Withdrawal by subject | 26 | 2 |
| Withdrew: Requirement for alternative therapy | 11 | 1 |
| Withdrew: Physician decision | 7 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Death | 15 | 0 |
| Withdrew: Protocol-specified criteria | 3 | 0 |
| Withdrew: Pregnancy | 1 | 0 |
| Withdrew: Other | 11 | 0 |
Participants with one or more occurrences of one or more adverse events up to 8 weeks after the end of treatment. Participants with more than one event were only counted once.
| Participants | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| Number of Participants With Adverse Events | 284 | 19 |
Platelet response was defined as having a platelet count of ≥ 50 x 10\^9/L at any time on study, excluding platelet counts within 8 weeks after receiving any rescue medications.
| Participants | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| Number of Participants With a Platelet Response | 275 | 20 |
The number of participants with a reduction or discontinuation of concurrent immune (idiopathic) thrombocytopenic purpura (ITP) therapies (corticosteroids, danazol, azathioprine) during the study.
| Participants | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| Number of Participants With a Reduction or Discontinuation of Concurrent ITP Therapies | 30 | 1 |
The ITP Patient Assessment Questionnaire (ITP-PAQ) assesses ITP-specific health-related quality of life (HRQOL). This questionnaire assesses ITP specific health-related quality of life (HRQOL). The questionnaire consists of 44 items and has six domains: These domains assess the impact of ITP on Physical Health, Mental Health, Work, Social Activity, Women's Health and Overall QOL. The impact of ITP on Physical Health consists of four sub-scales, which evaluate ITP related Symptoms, Fatigue, Bother and Activity. The impact of ITP on Mental Health consists of two sub-scales, which evaluate Psychological distress and Fear in a population with ITP. Items are scored from 0-100 with higher scores indicating better HRQOL.
| scores on a scale | Romiplostim in Adults |
|---|---|
| Physical Health Symptoms (N=209) | 4.20 ± 13.15 |
| Physical Health Fatigue (N=208) | 3.99 ± 16.00 |
| Physical Health Bother (N=204) | 6.43 ± 17.39 |
| Physical Health Activity (N=208) | 5.23 ± 21.08 |
| Emotional Health Psychological (N=208) | 4.01 ± 15.81 |
| Emotional Health Fear (N=209) | 3.48 ± 12.59 |
| Overall Quality of Life (N=210) | 8.32 ± 19.65 |
| Social Quality of Life (N=209) | 3.89 ± 13.41 |
| Women's Reproductive Health (N=71) | 4.51 ± 16.35 |
| Work Quality of Life (N=75) | 2.78 ± 14.54 |
The SF-36 is a widely used generic health-related quality of life measure. It has 36 questions with 8 domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Items are scored from 0 to 100 with higher scores indicating better health status.
| scores on a scale | Romiplostim in Adults |
|---|---|
| Physical Functioning (N=206) | 1.38 ± 6.34 |
| Role-Physical (N=208) | 2.03 ± 8.89 |
| Bodily Pain (N=206) | 0.94 ± 7.99 |
| General Health Perception (N=208) | 1.31 ± 7.03 |
| Vitality (N=208) | 1.68 ± 7.47 |
| Social Functioning (N=208) | 0.52 ± 8.21 |
| Role-Emotional (N=205) | 1.75 ± 12.22 |
| Mental Health Index (N=208) | 0.91 ± 7.45 |
| Physical Component Summary (N=200) | 1.49 ± 6.51 |
| Mental Component Summary (N=200) | 1.06 ± 8.80 |
The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The instrument is applicable to a wide range of health conditions and treatments and results in a single index score and a visual analog scale (VAS) score. The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension comprises three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state is defined by combining one level from each of the five dimensions. EQ-5D index values range from -0.59 to 1.00. Higher EQ-5D Index scores represent better health status.
| scores on a scale | Romiplostim in Adults |
|---|---|
| Change From Baseline in Euroqol-5D (EQ-5D) Index Score | 0.03 ± 0.16 |
The EQ-5D is a patient-completed, multidimensional measure of health related quality of life. The EQ-5D VAS records the respondent's self-rated health status on a vertical graduated (0-100) visual analogue scale. Higher EQ-5D VAS scores represent better health status.
| scores on a scale | Romiplostim in Adults |
|---|---|
| Change From Baseline in Euroqol-5D (EQ-5D) Visual Analogue Scale (VAS) | 6.05 ± 14.85 |
The Patient Global Assessment is two questions which assess the overall health-related quality of life (HRQOL) and symptoms of the patient. Each item is answered on a 15-point Likert scale ranging from 'A very great deal worse' (1) to 'A very great deal better' (15). A higher score indicates that quality of life or symptoms have improved.
| scores on a scale | Romiplostim in Adults |
|---|---|
| Week 1 (N=271) | 7.61 ± 2.02 |
| Week 48 (N=216) | 8.18 ± 1.78 |
Collected over For adult participants the average duration was 110 weeks; for pediatric participants the average duration is 82 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Romiplostim in Adults | — | 117/291 (40.2%) | 270/291 (92.8%) |
| Romiplostim in Pediatric Population | — | 2/20 (10%) | 18/20 (90%) |
| Event | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 23/291 | 0/20 |
| Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders | 7/291 | 1/20 |
| InfluenzaInfections and infestations | 0/291 | 1/20 |
| Pharyngitis streptococcalInfections and infestations | 0/291 | 1/20 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 3/291 | 1/20 |
| PneumoniaInfections and infestations | 8/291 | 0/20 |
| Cardiac failure congestiveCardiac disorders | 5/291 | 0/20 |
| Myocardial infarctionCardiac disorders | 5/291 | 0/20 |
| Bone marrow disorderBlood and lymphatic system disorders | 4/291 | 0/20 |
| Cardiac failureCardiac disorders | 4/291 | 0/20 |
| Event | Romiplostim in Adults | Romiplostim in Pediatric Population |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 76/291 | 10/20 |
| PyrexiaGeneral disorders | 36/291 | 9/20 |
| HeadacheNervous system disorders | 109/291 | 9/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 70/291 | 9/20 |
| PetechiaeSkin and subcutaneous tissue disorders | 53/291 | 9/20 |
| ContusionInjury, poisoning and procedural complications | 88/291 | 8/20 |
| VomitingGastrointestinal disorders | 46/291 | 7/20 |
| FatigueGeneral disorders | 93/291 | 7/20 |
| NasopharyngitisInfections and infestations | 100/291 | 5/20 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 30/291 | 6/20 |
| Age, Continuous(Years) | Romiplostim in Adults | Romiplostim in Pediatric Population | Total |
|---|---|---|---|
| Mean | 54.2 ± 16.9 | 10.2 ± 5.1 | 51.3 ± 19.7 |
| Sex: Female, Male(Participants) | Romiplostim in Adults | Romiplostim in Pediatric Population | Total |
|---|---|---|---|
| Female | 184 | 6 | 190 |
| Male | 108 | 15 | 123 |
| Race/Ethnicity, Customized(Participants) | Romiplostim in Adults | Romiplostim in Pediatric Population | Total |
|---|---|---|---|
| Black or African American | 13 | 3 | 16 |
| White or Caucasian | 246 | 13 | 259 |
| Hispanic or Latino | 21 | 4 | 25 |
| Asian | 9 | 0 | 9 |
| Japanese | 1 | 0 | 1 |
| American Indian or Alaska Native | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Other | 0 | 1 | 1 |
No study locations are listed for this record.
The record gives a start of Aug 2004, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim
Purpura, Thrombocytopenic, Idiopathic →